Snapdragon Chemistry Names Hui Fang to Head GMP Analytical Lab


Waltham, MA – July 7, 2021 – Snapdragon Chemistry today announced the hiring of Dr. Hui Fang as the company’s Director of Attribute Sciences and Quality Control. As a part of the company’s leadership team, Dr. Fang will lead the Snapdragon’s analytical group to offer a suite of analytical services for customers’ clinical and commercial assets, and the GMP QC lab, which is scheduled to open in Q1 2022 in Waltham, Massachusetts.

“Hui brings us with over a decade of experience in development and manufacturing for clinical and commercial pharmaceutical drug substances and drug products,” says Snapdragon Chief Scientific Officer Eric Fang. “With his expertise in analytical sciences and GMP quality control, and an impeccable track record of marketed drugs and research publications, Hui will bring tremendous value to Snapdragon and our clients. As we continue our rapid expansion in process development and GMP manufacturing, his expertise will meet the customers’ analytical needs from IND to NDA.”

“I am thrilled and honored to join such a stellar team of scientists and engineers, and to lead the analytical team to enhance Snapdragon’s offering in analytical development and quality control,” said Dr. Fang. “Snapdragon is a well-known brand, an industry leader when it comes to innovation and technology. I am excited to apply my knowledge in elevating their platform, delivering quality products to clients, and leading projects in the new GMP lab facility at 360 Second Avenue.”

Dr. Fang brings years of experience and an in-depth knowledge of pharmaceutical R&D and regulatory compliance to Snapdragon. During that time, he gained a reputation for exceptional project management skills, problem-solving, expertise of drug analysis and characterization by various analytical technologies.

Dr. Fang comes to Snapdragon after almost two years as Associate Director, CMC Analytical Development at Akebia Therapeutics in Cambridge, MA. At Akebia, he led analytical scientists to support day-to-day commercial manufacturing operations of Auryxia® drug substance and drug product by seven CMOs in multiple countries. He also provided scientific guidance and technical oversight for CMOs, CROs and CDMOs including method development, analytical testing and reporting, and trend analysis.

Prior to that, Dr. Fang worked his way from scientist to principal scientist at Eisai Inc. in Andover, MA, leading an impressive list of clinical and commercial-stage small molecules and biologics projects. Noticeably, Dr. Fang is a part of the team to bring a highly complex small molecule cancer therapeutics Halaven® (erbulin mesylate) to the market.

Dr. Fang obtained his Ph.D. from University of Pittsburg and B.Sc. M.Sc. from Nankai University in Tianjin, China. He is also affiliated with American Chemical Society (ACS) and American Association of Pharmaceutical Scientists (AAPS).

About Snapdragon Chemistry
Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff. For more information, please contact